businesspress24.com - Dr. Albert D. Friesen to File Early Warning Report
 

Dr. Albert D. Friesen to File Early Warning Report

ID: 1315833

(firmenpresse) - WINNIPEG, MANITOBA -- (Marketwired) -- 11/05/14 -- Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE: MPH)(OTCQB: MCUJF), a specialty pharmaceutical company, today reports that since March 1, 2013 Dr. Albert D. Friesen has acquired 299,308 common shares which exceeds 2% of the outstanding common shares of Medicure. This 2% reporting threshold was reached on November 4, 2014 with the acquisition of 150,408 common shares of Medicure representing approximately 1.22% of the Company''s outstanding common shares (the "Acquisition"). The shares, which are still subject to approval of the TSX Venture Exchange ("TSXV"), will be issued by the Company at a deemed price of $1.98 per share in order to settle outstanding fees payable to Dr. Friesen for past services rendered to the Company up to July 11, 2014 (the "Settlement"). The Settlement was approved by the disinterested shareholders of the Company at its annual and special meeting of shareholders held on November 4, 2014. Dr. Friesen may in the future acquire additional shares in the Company, if deemed appropriate to do so in his sole discretion.

Subject to TSXV approval of the Acquisition, Dr. Friesen owns or exercises control over 2,443,955 common shares of Medicure, representing approximately 19.68% of the Company''s issued and outstanding common shares. Dr. Friesen also holds stock options entitling him to purchase an aggregate of 516,500 common shares of Medicure upon exercise of the options, bringing his total to 2,960,455 common shares or approximately 22.89% of Medicure''s issued and outstanding common shares on a partially diluted basis.

The above information has been provided to the Company by Dr. Friesen, of 1250 Waverley Street, Winnipeg, Manitoba, for inclusion in this news release. An Early Warning Report respecting the Acquisition will be filed electronically on the Company''s SEDAR profile and anyone wishing to obtain a copy of the Report may contact Dawson Reimer at 888-435-2220.





To be added to Medicure''s e-mail list, please visit:

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.



Contacts:
Medicure Inc.
Dawson Reimer
888-435-2220
204-488-9823 (FAX)


Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Spectral Provides Update on Its Path to Commercialization
Cell MedX Corp. (CMXC), Announces the formation of an Advisory Board with John Sanderson MD as Chairman
Bereitgestellt von Benutzer: Marketwired
Datum: 05.11.2014 - 11:33 Uhr
Sprache: Deutsch
News-ID 1315833
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

WINNIPEG, MANITOBA


Phone:

Kategorie:

Medical Devices


Anmerkungen:


Diese Pressemitteilung wurde bisher 151 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Dr. Albert D. Friesen to File Early Warning Report
"
steht unter der journalistisch-redaktionellen Verantwortung von

Medicure Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Medicure Inc.



 

Who is online

All members: 10 563
Register today: 0
Register yesterday: 2
Members online: 0
Guests online: 62


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.